January 2001
Lupus;Jan2001 Supplement 1, Vol. 10, pS117
Academic Journal
An abstract of the article "Improving the Utility of ACR Criteria for Clinical Trials" is presented. The authors discuss the standards for the eligibility of clinical trials for patients with sytematic lupus erythematosus. Moreover, they conclude that inclusion of patients with milder disease would minimize selection bias and increase the generalizability of clinical trials.


Related Articles

  • Responsiveness and sensitivity to change of SLE disease activity measures. Corzillius, M; Fortin, P; Stucki, G // Lupus;1999, Vol. 8 Issue 8, p655 

    The ability of outcome measures to detect change over time is critical for their usefulness in clinical trials. Two concepts are applied in the assessment of evaluative instruments: We endorse the recommendation that a distinction be made between sensitivity and responsiveness. Sensitivity to...

  • Recruitment strategies in superiority trials in SLE: lessons from the study of methotrexate in lupus erythematosus (SMILE). Ferland, Diane; Fortin, Paul R // Lupus;1999, Vol. 8 Issue 8, p606 

    The task of recruiting patients for a research project can prove to be the most difficult aspect of the entire research process. A large portion of the work of research is devoted to the identification of strategies which ensure a successful recruitment of patients. Every researcher has learned...

  • Classification and definition of major flares in SLE clinical trials. Petri, Michelle; Buyon, Jill; Kim, Mimi // Lupus;1999, Vol. 8 Issue 8, p685 

    Multiple reliable and valid disease activities indices exist and have been used successfully in longitudinal studies. However, the definition of flare, using these intruments, has not been universally decided or accepted. Because flare is one of the three major patterns of lupus activity, it...

  • Lupus and Nutrition. Volpenhein, Linda M. // MMRC Health Educator Reports;2010, p1 

    The article discusses the types of lupus and its treatment. Lupus is considered as an autoimmune disorder that affects many systems of the human body. It can be discoid lupus erythematosus, systemic lupus erythematosus, or drug-induced lupus erythematosus. It is recommended that patients with...

  • Response and remission criteria for clinical trials in lupus—what can we learn from other diseases? Schneider, M // Lupus;1999, Vol. 8 Issue 8, p627 

    Focuses on clinical trials for the treatment of systemic lupus erythematosus (SLE). Phenotype of SLE; Assessment of complete response (CR) in the disease; Valuation of CR in the development of remission criteria for the disease.

  • Methodological issues of corticosteroid use in SLE clinical trials. Corzillius, M; Bae, S-C // Lupus;1999, Vol. 8 Issue 8, p692 

    Objective: To describe and analyze how investigators handled concurrent steroid intake in SLE clinical trials; to identify remaining methodological problems and to discuss potential solutions. Methods: A review of the literature was performed in Medline to identify randomized controlled trials...

  • Early stopping of clinical trials in lupus and other uncommon rheumatologic diseases. LaValley, Michael P; Felson, David T // Lupus;1999, Vol. 8 Issue 8, p698 

    Use of statistical methods for early stopping of clinical trials allows more efficient and ethical utilization of subjects. In uncommon diseases, where the pool of potential subjects is limited, these methods provide a way to maximize the information gathered from trials. For trials in lupus,...

  • Quality of life and economic evaluation in SLE clinical trials. Gordon, Caroline; Clarke, Ann E // Lupus;1999, Vol. 8 Issue 8, p645 

    Outcome in SLE patients should include assessment of disease activity and chronic damage and also measurement of health-related quality of life and the economic impact of the disease. This paper reviews the methods available for doing this and the results of existing studies in SLE patients.

  • The SLICC/ACR damage index: progress report and experience in the field. Gladman, D D; Urowitz, Murray B // Lupus;1999, Vol. 8 Issue 8, p632 

    The SLICC/ACR damage index for SLE was developed to assess accumulated damage since the onset of the disease. The damage includes non-reversible changes in organs and systems affected by the disease process itself, its therapy, or inter-current illness. This paper describes the development of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics